Key takeaways:

An analysis of patients treated with immune checkpoint inhibitors for NSCLC showed a significantly lower response rate among those on steroids at baseline.

Steroid users also had shorter PFS and OS.

A medication often prescribed to reduce symptoms among people with lung cancer limits the effectiveness of certain treatments, according to retrospective study results.

Patients with non-small cell lung cancer who used corticosteroids at the time they started immune checkpoint inhibitor therapy had inferior outcomes, including a lower rate of response. Steroid users also had shorter PFS and OS.

Data derived from Polyakov L, et al. Cancer Res Commun . 2025;doi:10.1158/2767-9764.CRC-25-0051.

Jorge Nieva

“We have known for decades that steroids impact immune function. Wha

See Full Page